Precision oncology treatment Vitrakvi (larotrectinib) is approved for the treatment of adults and paediatric patients with locally advanced or metastatic solid tumours that have a rare genomic alteration called an NTRK gene fusion
/PRNewswire/ Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the addition of a companion.
Collaboration will strengthen and amplify identification of patients with Neurotrophic Tyrosine Receptor Kinase (NTRK) fusion-positive solid tumors potentially.
Bayer transforms pharma business through breakthrough innovation in healthcare 13:48 | 14/01/2021
Bayer has made exciting progress in transforming its pharmaceutical business with breakthrough innovations in healthcare that will significantly help patients suffering from conditions that are currently still difficult to treat.
Bayer highlighted its focus on cell, gene, and oncology pipelines during its virtual Pharma Media Day in Germany
The information was stressed at its virtual Pharma Media Day titled âTransforming Healthcare. Transforming Bayerâ in Germany. The event highlighted Bayer s focus on the cell, gene, and oncology pipelines.
âThe biomedical and technological revolution that is transforming healthcare at an unprecedented pace is taking place now. Our company is at the forefront of the wave of innovation in cell and gene therapy as well as digital health,â said Stefan Oelrich, member of the board of management at Ba